Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-211.58M |
| EBITDA | $-407.97M |
| Operating Margin | 0.00% |
| Return on Equity | -138.90% |
| Return on Assets | -54.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.26 |
| Price-to-Book | 20.89 |
| Price-to-Sales (TTM) | 13.14 |
| EV/Revenue | 8.22 |
| EV/EBITDA | -2.08 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $119.83M |
| Float | $91.86M |
| % Insiders | 0.76% |
| % Institutions | 116.11% |
Volatility is currently expanding